Testosterone treatment comes of age: new options for hypogonadal men
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary: Male hypogonadism is one of the most frequent, but also most underdiagnosed, endocrinopathies. However, the required testosterone treatment is simple and very effective if properly administered. Although testosterone has been available for clinical use for seven decades, until quite recently the treatment modalities were far from ideal. Subdermal testosterone pellets require minor surgery for insertion and often cause local problems. The injectable testosterone enanthate, for a long period the most frequently used mode of administration, lasts for two to four weeks, but produces supraphysiological levels initially and low levels before the next injection. The oral testosterone undecanoate has to be taken three times daily, has an uncertain absorption pattern and results in peaks and valleys of serum testosterone levels throughout the day. With the advent of transdermal testosterone preparations, the desired physiological serum levels could be achieved for the first time. Scrotal testosterone patches were the first to fulfil this requirement. These were followed by nonscrotal skin patches, which, however, cause considerable skin reactions including erythema and blisters. Recently introduced, invisible transdermal testosterone gels increased the intervals of application and are now slowly replacing other modalities. A mucoadhesive buccal testosterone tablet with sustained release is also a recent competing modality. Finally, injectable testosterone undecanoate in castor oil was made into a real depot preparation requiring only four injections per year for replacement therapy. These new preparations with a desired pharmacokinetic testosterone profile give the patient a real choice and make treatment easier. Based on pharmacogenetic considerations taking the androgen receptor polymorphism into account, treatment may be individualized for each patient in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381
NIESCHLAG, E., SWERDLOFF, R., BEHRE, H. M., GOOREN, L. J., KAUFMAN, J. M., LEGROS, J. ‐., LUNENFELD, B., MORLEY, J. E., SCHULMAN, C., WANG, C., et al. (2005) · International Journal of Andrology · doi:10.1111/j.1365-2605.2005.00553.x · Cited by 282
Self-citationTestosterone replacement therapy: current trends and future directions
Nieschlag, E., Behre, H. M., Bouchard, P., Corrales, J. J., Jones, T. H., Stalla, G. K., Webb, S. M., & Wu, F. C. W. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh035 · Cited by 224
Self-citationMcNicholas, T. A., Dean, J. D., Mulder, H., Carnegie, C., & Jones, N. A. (2003) · BJU International · doi:10.1046/j.1464-410x.2003.04016.x · Cited by 178
Nieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Self-citation
Cited by
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Self-citationTransdermal patches: history, development and pharmacology
Pastore, M. N., Kalia, Y. N., Horstmann, M., & Roberts, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13059 · Cited by 586
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J. ‐., Lunenfeld, B., Morales, A., et al. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 445
Self-citationThe benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2009) · European Urology · doi:10.1016/j.eururo.2008.08.033 · Cited by 345
Self-citationWang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2009) · International Journal of Impotence Research · doi:10.1038/ijir.2008.41 · Cited by 288
Self-citationTraish, A. M., Goldstein, I., & Kim, N. N. (2007) · European Urology · doi:10.1016/j.eururo.2007.02.034 · Cited by 268
Onset of effects of testosterone treatment and time span until maximum effects are achieved
Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232
Zitzmann, M., & Nieschlag, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0620 · Cited by 216
Self-citationSaad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.002774 · Cited by 132
Andersen, M. L., & Tufik, S. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.12.003 · Cited by 118
Saad, F., Gooren, L., Haider, A., & Yassin, A. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00807.x · Cited by 89
“…have been extensively studied: T gel is a daily application (Wang et al., 2004) and for TU, the first two injections of 1000 mg TU are to be administered with an interval of 6 weeks (‘loading dose’), followed by injections every 12 weeks (Schubert et al., 2004; Harle et al., 2005; Nieschlag, 2006).”
BackgroundMethodInfluentialSaad, F., Gooren, L., Haider, A., & Yassin, A. (2007) · Archives of Andrology · doi:10.1080/01485010701730880 · Cited by 87
Jacobeit, J. W., Gooren, L. J., & Schulte, H. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0412 · Cited by 73
Yeap, B. B., Almeida, O. P., Hyde, Z., Chubb, S. A. P., Hankey, G. J., Jamrozik, K., & Flicker, L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03055.x · Cited by 65
Late-Life Onset Hypogonadism: A Review
Bassil, N., & Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.02.003 · Cited by 59
“Although it is not yet clear what critical threshold is a desirable, dose adjustment or periodic phlebotomy may be necessary to keep hematocrit less than 52% to 55%.(45,58,186)”
Moon, D. G., Park, M. G., Lee, S. W., Park, K., Park, J. K., Kim, S. W., Park, N. C., Ahn, T. Y., Paick, J. S., Seo, J. T., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01765.x · Cited by 46
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
Jockenhövel, F., Minnemann, T., Schubert, M., Freude, S., Hübler, D., Schumann, C., Christoph, A., Gooren, L., & Ernst, M. (2009) · The Aging Male · doi:10.3109/13685530903322858 · Cited by 31
“The latter is a rather novel testosterone preparation [1,2].”
Background
Metadata
- Authors
- Nieschlag, E.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2006-07-18
- Volume
- 65
- Issue
- 3
- Pages
- 275-281
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2129132699
- Cited by
- 136
- References
- 11
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.